Kidney Cancer News and Research

RSS
Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.
Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics announces fourth-quarter and full-year 2009 financial results

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

US HIFU announces exclusive partnership with Riverside Research Institute

US HIFU announces exclusive partnership with Riverside Research Institute

Pazopanib drug slows the progression of RCC in patients by 54%

Pazopanib drug slows the progression of RCC in patients by 54%

Prometheus Laboratories executes commercialization agreement with Novartis

Prometheus Laboratories executes commercialization agreement with Novartis

Pfizer reports final results from randomized Phase 3 trial of Sutent

Pfizer reports final results from randomized Phase 3 trial of Sutent

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Health Canada approves Novartis' Afinitor to treat patients with mRCC

Mutations in genome regulation machinery identified in clear cell renal cell carcinoma

Mutations in genome regulation machinery identified in clear cell renal cell carcinoma

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

University of Wisconsin IRB approves GenSpera's G-202 Phase I study for cancer

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

Health experts discuss new treatment strategies for lung cancer at AACR-IASLC Joint Conference

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

Cancer researchers find a way to turn ineffective new cancer drugs into cancer-fighters

Antigenics to withdraw its MAA for Oncophage following CHMP’s negative opinion

Antigenics to withdraw its MAA for Oncophage following CHMP’s negative opinion

2nd EMUC Meeting to discuss urological cancer

2nd EMUC Meeting to discuss urological cancer

Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer

Bayer's NEXAVAR approved in over 70 countries for the treatment of liver cancer

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.